Compare BOH & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOH | RARE |
|---|---|---|
| Founded | 1897 | 2010 |
| Country | United States | United States |
| Employees | 1877 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | N/A | 2013 |
| Metric | BOH | RARE |
|---|---|---|
| Price | $85.31 | $29.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $85.40 | $59.10 |
| AVG Volume (30 Days) | 378.7K | ★ 3.0M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $15.66 | $13.12 |
| Revenue Next Year | $7.82 | $37.80 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $59.36 | $18.29 |
| 52 Week High | $86.31 | $39.89 |
| Indicator | BOH | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 66.18 | 47.65 |
| Support Level | $75.65 | $29.08 |
| Resistance Level | N/A | $36.26 |
| Average True Range (ATR) | 1.73 | 1.76 |
| MACD | 0.23 | -0.62 |
| Stochastic Oscillator | 83.33 | 9.78 |
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.